New Emerging Stem Cell Index
Shares of Geron (GERN) and other well known stem cell and regenerative medicine stocks such as Osiris Therapeutics (OSIR) and StemCells (STEM) have been soaring since the FDA allowed human clinical testing for Geron's embryonic stem cell treatment candidate for spinal cord injuries.
The table at my website link below highlights 25 U.S.-listed stem cell and regenerative medicine companies with market caps of below $200M which are included in the ETF Innovators Emerging Stem Cell Index. The companies are also listed below in descending order by market cap.
BioMimetic Therapeutics (BMTI)
Cytori Therapeutics (CYTX)
RTI Biologics (RTIX)
Aastrom Biosciences (ASTM)
Mesoblast (MBLTY)
Neuralstem (CUR)
Osteotech (OSTE)
ThermoGenesis (KOOL)
RegeneRx Biopharma (RGN)
Advanced Cell Tecchology (ACTC)
Pluristem Therapeutics (PSTI)
Athersys (ATHX)
International Stem Cell Corp (ISCO)
Stem Cell Innovations (SCLL)
Bioheart (BHRT)
CellCyte Genetics Corp (CCYG)
Stem Cell Therapeutics (SCTPF)
Brainstorm Cell Therapeutics (BCLI)
Opexa Therapeutics (OPXA)
Stem Cell Authority (SCAL)
Neostem (NBS)
Stem Cell Therapy Internt'l (SCII)
Cord Blood America (CBAI)
MultiCell Technologies (MCET)
LifeStem International (LSTM)
While regenerative medicine holds enormous potential for breakthrough medical treatments, investors and traders should be cautious as the entire space is an extreme momentum trade since the FDA news to allow human testing of embryonic stem cells. President Obama is also expected to lift the federal ban under the previous administration to allow federal funding of stem cell research, providing another boon to these companies.
Click here for my previous articles on
stem cell investing , including my favorite two companies from this index – Cytori Therapeutics and ThermoGenesis, which are developing therapeutic and stem cell banking applications derived from a patient's own fat tissue and blood or bone marrow, respectively. Both of these companies already have products on the market, in addition to ongoing clinical studies for therapeutic applications of their stem cell and regenerative medicine systems and technology platforms.
$7.5 (02/02/09)
